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effectiveness ratio (ICER). Bootstrapping technique was applied for assessing
uncertainty in cost-effectiveness analyses. The robustness of findings was tested
in sensitivity analyses. RESULTS:Although there were no significant differences in
medication adherence and hospitalization outcomes between two groups, patients
in CR programs had a gradually improved medication adherence and lower hospi-
talization over time. Mean annual costs (2003 value) were $3172 and $2092 per
patient for CR group and control group, respectively. The ICER was $538 for 1%
improvement inmedication adherence and $1080 for an additional hospitalization
avoided. CONCLUSIONS: CR programs offered benefits of improving medication
adherence and reducing hospitalization over time although it was costly in the
beginning of its provision. Trade-off of increase in costs for the increase in benefits
should be considered.
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OBJECTIVES: To analyze the cost-effectiveness of treating hypertensive patients
with azilsartan medoxomil and chlorthalidone fixed dose combination (AZL-M/
CLD FDC) therapy compared with other angiotensin receptor blocker (ARB) and
hydrochlorothiazide (HCT) combinations commonly available in the US market.
METHODS:AMarkov Cohort Simulation approachwas utilized. Simulated patients
start in a hypertensive state and are followed over multiple time periods as they
transition betweenmutually exclusive health states. Cost per Quality Adjusted Life
Year (Cost/QALY) and Incremental Cost-effectiveness Ratios (ICERs) are calculated
over all possible dose combinations. Cardiovascular disease (CVD) riskswere based
on the Framingham risk equations. FDCs of HCT and eight ARBs commonly used in
the US market (Atacand HCT, Avalide, Benicar HCT, Hyzaar, Diovan HCT, generic
Losartan HCT, Micardis HCT and Teveten HCT) were included in the analyses.
RESULTS: Results suggest that AZL-M/CLD FDC is less expensive and more effec-
tive in lowering BP versus all branded ARB/HCT FDC comparators. When consider-
ing average costs and the CVD risks based on the Framingham risk equations for all
therapies over a five year time horizon, AZL-M/CLD FDC would remain the least
expensive andmost effective branded ARB/Diuretic FDC therapy up to a 23.5% unit
cost increase with the average office SBP reduction of -22.3% and up to 18.1% unit
cost increase with the 24-hour ambulatory BP reduction of -17.0%. CONCLUSIONS:
AZL-M/CLD FDC is predicted to be less expensive and more effective in reducing
blood pressure and cardiovascular risk when compared to all branded ARB/HCT
FDC comparators during a five year time horizon.
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OBJECTIVES: To estimate the cost-effectiveness of Dabigatran compared to War-
farin in non-complicated atrial fibrillation in Colombia.METHODS:We developed
a Markov model to represent the health states of atrial fibrillation and its compli-
cations;6 health states and 2 transitional states were considered,including dis-
abling and non-disabling stroke, myocardial infarction, pulmonary embolism and
death. Major andminor hemorrage were considered transitory in the model. Prob-
abilities were derived from published clinical trials. Resource use was estimated
from the Colombian Society of Cardiology guidelines and validated to adjust to
usual practice. Directmedical costswere derived fromdifferent sources (public and
private) and indirect costs (predicted wages lost and transportation costs) were
obtained from the most recent National Health Survey. Utilities were obtained
from a systematic literature review. Two separate analysis, payer and societal
perspective, were performed in a 20-year horizon. Maximum andminimum values
of effectiveness and resource use were included in the sensitivity analysis. The
results were discounted at 3% annually. RESULTS: After 20 years of follow up,
discounted direct medical costs accounted for USD$70,500 for Warfarin and
$78,840 and $79,860 for 150mg and 110mg of Dabigatran, respectively.When taking
into account indirect costs,Warfarin increased their costs by 13%while Dabigatran
costs were increased by 9%. Estimated life years for Dabigatran were higher (9.40
and 9.29 for 150mg and 110mg, respectively) as well as the QALYs (8.48, 8.39) than
for Warfarin 9.09 LY and 8.12 QALYs. The calculated ICER was $23,760 and $34,690
per additional QALY when taking into account direct costs and even lower when
considering indirect costs. CONCLUSIONS: In Colombia, the use of Dabigatran for
the management of non-complicated atrial fibrilation compared to Warfarin in-
creases years of life and QALYs. Assuming a similar willingnes-to-pay as for other
cardiovascular interventions, dabigatran is a cost-effective intervention.
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OBJECTIVES: To assess the cost-effectiveness of urapidil compared with standard
treatment of hypertension urgenciesMETHODS: A decision tree was used to sim-
ulate the effects of urapitil and standard therapy drugs such as captopril, clonidine,
nifedipine, metoprolol, magnesium sulphate, furosemide, enalaprilat. Standard
therapy drugs were revealed after observational study of prehospital treatment of
hypertension crisis. The efficacy of drugs was obtained from clinical trials, while
medical care costs were estimated from standard of treatment of hypertension
urgencies developed and published by Ministry of public health. A cost-effective-
ness ratio of urapidil was compared with other drugs. At the last stage double
phase sensitivity analysis was conducted. RESULTS: A CER of urapidil was the
lowest (1942.89 RUB/64.73$) in comparison to another drugs (captopril-1966.34
RUB/65.53$; metoprolol-2191.43 RUB/73.03$; enalaprilat - 2443.52 RUB/81.45$; ni-
fedipine-2485.71 RUB/82.83$; furosemide-2505.53 RUB/83.5$; clonidine-2558.12
RUB/85.26$; ; magnesium sulphate -2932.92 RUB/97.73$). Sensitivity analysis dem-
onstrated stability of results, changing cost of hospitalization and cost of urapidil
the advantage of urapidil from the position of “cost-effectiveness” was still
obviously. CONCLUSIONS: Treatment of hypertension urgencies with urapidil is a
dominated alternative from the perspective of the health economics.
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OBJECTIVES: To compare the costs and effectiveness of dabigatran etexilate with
current standard treatment in patients with non-valvular atrial fibrillation (NVAF),
from the Slovakian health care system perspective. METHODS: A previously pub-
lishedMarkov cohortmodelwas adopted to estimate the outcomes of patientswith
dabigatran (150mg BID, 110mg BID) in its labelled indication during their lifetime
for the following health states: ischemic and haemorrhagic stroke, transient isch-
emic attack, systemic embolism, intracranial and extracranial haemorrhage, acute
myocardial infarction, minor bleeds and death. Data on event rates and patient
quality of life associated with different health states and patient survival time was
based on the RE-LY trial and the literature. The base-case consisted of a cohort of
patients with NVAF, CHADS21 and no contraindications to anticoagulation ther-
apy. Themodelled consequences of the clinical eventswere costs, disability and/or
reduction in quality of life and death. Data on resource use associated with patient
management and different events were estimated using a Slovakian expert panel,
while unit prices were collected from the official sources update 2011. One-way
sensitivity analyses was used on all relevant variables to test the robustness of the
analysis. RESULTS: The dabigatran group had more life years and QALYs gained
compared to standard treatment (warfarin, aspirin, clopidogrel and no treatment);
these gains were primarily driven by a lower incidence of the intracranial events
and systemic embolism. A cohort of 5,000 patients treated with dabigatran during
their lifetime gained 40,238QALYs (standard: 38,178QALYs)with incremental costs
of €35.9mill (standard: €37.3mill). The incremental cost-effectiveness ratio (ICER) of
dabigatran versus standard treatment was estimated at €17,437, below the Slovak-
ian acceptable threshold (€18,000 per QALY gained). The sensitivity analysis con-
sistently demonstrated the cost-effectiveness of dabigatran. CONCLUSIONS: Dab-
igatran represents a cost-effective treatment for preventing strokes in patients
with NVAF in Slovakia.
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OBJECTIVES: Dabigatran was approved in the United States to reduce the risk of
stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF).
Dabigatran has several potential advantages over the current standard of care
(warfarin), including a generally better side effect profile, fewer drug interactions,
and no international normalized ratio (INR)monitoring, but it is considerablymore
expensive. The objective of this analysis was to determine the cost-effectiveness of
dabigatran versus warfarin for AF in a Medicare population.METHODS: A Markov
model was used to simulate outcomes for patients aged 65 with AF and a (CHADS2)
congestive heart failure, hypertension, age, diabetes, prior stroke [doubled] score
1. A 5-year time horizon and a managed care perspective were employed in this
analysis. Data comparing the clinical performance of dabigatran and warfarin was
derived from the RE-LY trial. Quality-adjusted life-years (QALYs) were used to as-
sess outcomes and utility weights were obtained from systematic reviews. Direct
medical costs associated with complications from AF were based on hospitaliza-
tion costs for diagnostic-related groups and reported in U.S. 2011 dollars. RESULTS:
Over a 5-year period, the incremental cost-effectiveness ratio (ICER) for dabigatran
150 mg was $26,551 per QALY compared to warfarin. The ICER was most sensitive
to the utility associatedwith thewell state for each of the alternatives aswell as the
price of dabigatran, warfarin, and INR monitoring needed for warfarin therapy. In
probabilistic analyses, dabigatran was cost-effective in 91% of simulations at a
$50,000/QALY threshold. CONCLUSIONS: Prescribing dabigatran increases quality-
adjusted life expectancy for AF patients at a cost considered acceptable by Amer-
ican payers.
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OBJECTIVES: To compare cost-effectiveness of rosuvastatin (RSV) versus
ezetimibe/simvastatin (E/S) in achieving LDL-C goals (NCEP-ATP III 2001 and 2004
guidelines), in daily outpatient practice in Mexico.METHODS: Retrospective study.
From January 2004 to December 2010, outpatient medical records in 15 Mexican
hospitals/clinics were reviewed to identify patients with dyslipidemia and their
corresponding serum lipidmeasurements documented before receiving drug ther-
apy with either RSV (5mg, 10mg, or 20mg once daily) or E/S (5/5mg, 10/10mg, 10/
20mg or 10/40mg once daily); and lipid levels recorded at least after 8 weeks of
treatment. The efficacywas assessed by a) the proportion of patients who achieved
the LDL-C goal, and b) the percent reduction in LDL-C after 8 weeks of treatment. A
cost-effectiveness analysis was performed from an institutional perspective, using
the exchange rate of August 2011 of 12.2424 pesos/USD. RESULTS: Using ATP III
2001 criteria, percentage of patients who reached LDL-C goals was RSV: 81.3% and
E/S 77.1% (p  0.2972). Using ATP III 2004 criteria were: RSV, 61.3% vs. E/S, 58.5%
(p0.2548). The average treatment cost was statistically significant higher for E/S
patients (239.49 USD) versus 192.74 USD for RSV patients (p0.0033). The cost of 1%
reduction in LDL-Cwas RSV: 4.69 USD and E/S: 7.13 USD. Cost per patient treated to
ATP-III goal 2001 criteria was: RSV, 219.5 USD versus E/S, 306.0 USD and treated to
ATP-III goal 2004 criteria was: RSV, 282.2 versus E/S, 459.1 USD. The overall inci-
dence rate of adverse events was E/S: 19.5% versus RSV: 15.3%. The percentage of
patients reporting moderate or severe adverse events was E/S: 6.8% and RSV: 4.7%.
CONCLUSIONS: According to this exploratory, non-controlled retrospective study,
in daily clinical practice in Mexican dyslipidemic patients, treatment with RSV has
similar efficacy and safety, but it is more cost-effectiveness than E/S in reaching
cholesterol goals.
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OBJECTIVES: To compare costs and effectiveness of dabigatran etexilate (DAB)
versus warfarin (WAR) in patients with Non-Valvular Atrial Fibrillation (NVAF)
from a private and public health care system perspective in Brazil. METHODS: A
Markov model was built to compare DAB versus WAR to derive the incremental
cost effectiveness ratio (ICER) of DAB, based on the international literature and a
modified Delphi panel with Brazilian experts (local clinical practice pattern on the
management of NVAF patients). The model estimated the number of ischaemic
and haemorrhagic strokes, systemic embolisms, intracranial hemorrhages, tran-
sient ischaemic attacks, extracranial hemorrhages, minor bleeds and acute myo-
cardial infarctions associated with the respective treatments. To each clinical
event costs, disabilities and/or reduction in quality of life, and risk of death were
assigned. Only direct medical costs were considered and a discount rate of 5% was
assumed, according to BrazilianHTA guidelines. A probabilistic sensitivity analysis
was designed to assess uncertainty. RESULTS: Under both, the private and public
perspective, DAB was associated with additional 0.30 life years gained (LY), addi-
tional 0.35 QALYs and demonstrated a lower incidence of intracranial events ver-
sus WAR, resulting in lower event costs and follow-up costs. The ICER for DAB
versus WAR was R$ 39,740/LY and R$ 34,867/QALY from the public and R$
25,252.48/LY and R$ 22,160.20/QALY from the private perspective. Sensitivity anal-
yses confirmed the cost-effectiveness of DAB. CONCLUSIONS: Findings suggest
that DAB can be cost-effective for stroke prevention when used instead of WAR in
NVAF patients in Brazil, given that the ICERS were below the threshold of other
technologies reimbursed.
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OBJECTIVES: To assess the cost-effectiveness of the novel fixed-dose anticogulant,
rivaroxaban, in comparisson to the current dose-volatile standard of care, warfa-
rin, for the prevention of stroke in high-risk atrial fibrillation patients.METHODS:
AMarkovmodel was constructed tomodel the costs and health outcomes of treat-
ments, potential adverse events, and resulting health states over 35 years. Analy-
ses were based on a hypothetical cohort of 65 year-old patients with chronic atrial
fibrillation and high risk of stroke. The main outcome measure was cost per qual-
ity-adjusted-life-years (QALYs) gained over the lifetime andwas assessed from the
UK’s National Health Service (NHS) perspective. Costs and utility data were drawn
from previously published and publically available data, while event probabilities
were adopted from both the literature and limited data from rivoroxaban’s phase
III trial. RESULTS: Stroke prophylaxis with rivaroxaban offers lifetime health im-
provements over warfarin treatment, yet at substantial cost. From the NHS’ per-
spective, rivaroxaban’s baseline cost of £38,121 per QALY exceeds the typical will-
ingness to pay threshold. Nonetheless, the results were sensitive to adjustments of
several key variables,most notably the price of rivaroxaban, utility of warfarin, risk
of bleeding-related eventswithwarfarin, anddiscount rate for outcomes, justifying
further consideration by NICE and the NHS. CONCLUSIONS: Novel anticoagulants
such as rivaroxaban are one of many strategies being considered to replace stan-
dard warfarin therapy andmitigate its compounding weaknesses of frequent dose
regulation and bleeding risk. Our results, though far from offering backbone for the
substitution of rivaroxaban for warfarin treatment across the NHS, justify atten-
tion to this and other fixed-dose therapies as a potential alternative to warfarin-
based stroke prevention strategies. In addition tomore detailed subgroup analysis,
further research ought to consider evaluating patient, caregiver, and indirect costs,
long-term impacts on health-system demand, and comparing novel anticoagula-
tion therapies against each other.
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OBJECTIVES: To estimate the cost-effectiveness of dronedarone in Turkey com-
pared to standard of care (SOC), amiodarone and sotalol as the cost per life-year
gained (LYG). METHODS: Cost-effectiveness of dronedarone compared to SOC,
amiodarone and sotalol was estimated in a health economic microsimulation
model with transition probabilities based on ATHENA trial and relative risks of
events for amiodarone and sotalol are taken from mixed treatment comparison
(MTC) based on a systematic review of the clinical trials of AF. There were 7 health
states; on anti-arrhythmic drug (AAD), off AAD, stroke, post-stroke, chronic heart
failure, post chronic heart failure, acute coronary syndrome, symptomatic AF and
death. Each simulation included 1,000,000 patients; in all simulations patients
were followed for life or end of simulation (max 28 years). Risk of having an adverse
event (AE) for patients on dronedarone compared to SOC was from ATHENA trial
and compared to amiodarone from theDIONYSOS trial. Costswere valued from the
Social Security Institution perspective using official price lists and App2/D dis-
counts. A Delphi survey was conducted with 8 specialists to estimate treatment
and hospitalization costs. RESULTS: Non-permanent AF patients taking droneda-
rone on top of SOC lived on average 0.14 years longer compared with SOC alone.
The incremental cost-effectiveness ratio (ICER) was estimated as 11,400TL/LYG.
When comparing dronedarone with amiodarone and sotalol, patients on droneda-
rone lived 1.17 years and 2.28 years longer respectively. The ICERs for dronedarone
compared to amiodarone and sotalol were estimated as 4,300TL/LYG and 3,100TL/
LYG, respectively. CONCLUSIONS: It is difficult for the results of the analysis to be
interpreted because there is no official cost-effectiveness threshold in Turkey.
From the WHO perspective, however, results showed that dronaderone is a highly
cost-effective treatment with all ICER values compared to SOC, amiodarone and
sotalol below 3 X GDP per capita; 70,857TL (3 X 23,619TL).
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OBJECTIVES: As far as combination of aspirin and clopidogrel was recently recom-
mended by Russian National Society of Cardiology as well as AHA “when oral
anticoagulation with warfarin is considered unsuitable”, the urgent need to com-
pare its cost-effeciveness with novel oral anticoagulant dabigatran is appear.
METHODS: Present study was based on Markov model with 10 years time horizon
simulated the cohort of 10 000 AF patients at moderate-to-high stroke risk while
tracking clinical events and resulting functional disability. Direct expenses associ-
ated with complications and resulting long-term follow-up costs were calculated
using general tariff agreement of Russian obligatory insurance system and official
national statistics. RE-LY, ActiveW trials and publishedmetaanalises were used as
main clinical data sources. Clinical events per 100 patient-years, total costs and
incremental cost effectiveness ratio (ICER) for both therapy regimens were evalu-
ated. The robustness and stability of the results were tested using sensitivity and
PSA analyses. RESULTS: Over a 10 years period patients treated with dabigatran in
comparison with those receiving dual antiplatelet therapy experienced fever isch-
emic strokes (1.8 vs. 3.49), extracranial bleedings (2.53 vs. 2.76) and hemorrhagic
strokes (0.41 vs. 0.44) per 100 patient-years. Total cost ofmedications accounted for
266,089 Roubles in dabigatran group and 249,870 Roubles in dual antiplatelet ther-
apy group, cost of complications treatment – 12,500 Roubles and 18,182 Roubles,
cost of follow-up after occurred complications and rehabilitation – 24987 Roubles
and 37620 Roubles per 100 patients respectively. In total, absolute cost-saving as-
sociated with dabigatran use was 20,948 Roubles per 100 patients. CONCLUSIONS:
Dabigatran use in stroke prevention in atrial fibrillation may be considered as
cost-saving alternative to aspirin plus clopidogrel combination in patients with
warfarin intolerance.
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OBJECTIVES: The reported impact of post-discharge therapeutic educational inter-
ventions (TEIs) in patients with cardiovascular diseases is controversial and has
been poorly addressed in cost-utility studies.We developed amodeling framework
for studying the cost-utility of TEIs in this setting. METHODS: We modeled the
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